Drug Updates

Methotrexate is a commonly used disease-modifying antirheumatic drug (DMARD) for treating patients with psoriatic arthritis (PsA). However, is it truly as effective as many think it is? That’s the question raised during the session “Spondylarthropathies: Recent Insights,” which took place at the 2011 ACR/ARHP Annual Scientific Meeting in November.

Rheumatoid Arthritis Drugs May Cut Cardiovascular Risk

Kathleen Louden | April 6, 2012

Other studies at the ACR/ARHP Annual Scientific Meeting in November examined arthritis treatment, scleroderma screening.

Biosimilar Drugs Face Challenges to Reach the U.S. Market

Kathleen Louden | March 8, 2012

To date, the FDA has not approved a biosimilar product. In its own discussion of the merits and obstacles to biosimilar drugs, the ACR sponsored a panel session titled, “Biosimilar Products in the U.S. Market: Fact or Fiction?” at the 2011 ACR/ARHP Annual Scientific Meeting here in November.

Where Will Kinase Inhibitors Fit into the RA Treatment Mix?

Vanessa Caceres | March 8, 2012

Presenters at “Looking Ahead to Kinase Inhibition in Rheumatoid Arthritis,” a session here at the 2011 ACR/ARHP Annual Scientific Meeting, delved into some of the big questions that rheumatology faces with kinase inhibitor use.

Information on New Drug Approvals and Medication Safety

Michele B. Kaufman, PharmD, BCGP | March 8, 2012

Rheumatology-related drug safety, approvals, and what’s in the pipeline.